Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Gracell Biotechnologies Inc ADR (NQ: GRCL ) N/A UNCHANGED Last Price Updated: 4:00 PM EST, Feb 21, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Gracell Biotechnologies Inc ADR < Previous 1 2 Next > Gracell Biotechnologies Acquisition Completed February 22, 2024 From Gracell Biotechnologies Inc. Via GlobeNewswire Gracell Biotechnologies Announces Shareholders’ Approval of Merger Agreement February 20, 2024 From Gracell Biotechnologies Inc. Via GlobeNewswire Gracell Biotechnologies Inc. (NASDAQ: GRCL) is a Stock Spotlight on 2/7 February 07, 2024 Via Investor Brand Network Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma January 29, 2024 Further expands clinical development of FasTCAR-T GC012F in multiple myeloma amid ongoing U.S. trial evaluating therapy for treatment of relapsed/refractory multiple myeloma From Gracell Biotechnologies Inc. Via GlobeNewswire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP) January 16, 2024 From Brodsky & Smith LLC Via GlobeNewswire AstraZeneca: Rebound in 2024 with double-digit earnings growth January 11, 2024 AstraZeneca's stock rose 8.95% in the past month on a bullish outlook, driven by growing sales of cancer and diabetes drugs and a strategic acquisition Via MarketBeat Exposures COVID-19 BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP) January 08, 2024 From Brodsky & Smith LLC Via GlobeNewswire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc. (Nasdaq – RYZB), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Daseke, Inc. (Nasdaq – DSKE), Karuna Therapeutics, Inc. (Nasdaq – KRTX) January 04, 2024 From Brodsky & Smith LLC Via GlobeNewswire GRACELL BIOTECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Gracell Biotechnologies Inc. - GRCL December 31, 2023 From Kahn Swick & Foti, LLC Via Business Wire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc. (Nasdaq – RYZB), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Daseke, Inc. (Nasdaq – DSKE), Karuna Therapeutics, Inc. (Nasdaq – KRTX) December 26, 2023 From Brodsky & Smith LLC Via GlobeNewswire GRCL Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Gracell Biotechnologies Inc. Is Fair to Shareholders December 26, 2023 From Halper Sadeh LLC Via Business Wire AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases December 26, 2023 From AstraZeneca Via Business Wire Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases December 26, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus December 21, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire Gracell Biotechnologies Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma at ASH 2023 December 11, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus November 27, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire Gracell Biotechnologies to Participate in Inaugural Cell Therapy for Autoimmune Disease Summit November 16, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire Gracell Biotechnologies Reports Third Quarter 2023 Unaudited Financial Results and Provides Corporate Update November 13, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire Gracell Biotechnologies Wins Overall Immunology Solution of the Year by BioTech Breakthrough Awards Program November 08, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire Gracell Biotechnologies to Present Updated Results from BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 65ᵗʰ American Society of Hematology Annual Meeting & Exposition November 02, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire Gracell Biotechnologies to Participate in Four Upcoming Investor Conferences November 01, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire Gracell Biotechnologies to Present Data Highlighting Preclinical Efficacy of SMART CART™ Against Solid Tumors at Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting October 31, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire Gracell Biotechnologies to Report Third Quarter 2023 Financials on Monday, November 13, 2023 October 30, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire Gracell Biotechnologies Reports Updated Clinical Data for FasTCAR-T GC012F for High-Risk, Newly Diagnosed Multiple Myeloma, Demonstrating 100% Stringent Complete Response Rate September 27, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire Gracell Biotechnologies Doses First Patient in Phase 1b/2 Clinical Trial in U.S. Evaluating GC012F for Treatment of Relapsed/Refractory Multiple Myeloma September 26, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire Gracell Biotechnologies’ CEO Dr. William Cao Named to Prestigious PharmaVoice 100, Honoring Most Inspiring Life Science Leaders September 19, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences September 14, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences August 24, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire Gracell Biotechnologies Reports Second Quarter 2023 Unaudited Financial Results and Provides Corporate Update August 14, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire Gracell Biotechnologies to Report Second Quarter 2023 Financials on Monday, August 14, 2023 July 31, 2023 From Gracell Biotechnologies Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.